1. Articles in category: Burden of Treatment

    1-24 of 168 1 2 3 4 5 6 7 »
    1. Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion.

      Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion.

      Oncol Rep. 2018 Feb 09;:

      Authors: Li C, Yang C, Wei G

      Abstract Resistance is the major cause of cisplatin treatment failure in neuroblastoma (NB). Vandetanib is widely used in the treatment of several cancers. In the present study, we aimed to determine the potential of vandetanib in cisplatin‑resistant NB therapy.

      Read Full Article
      Mentions: Treatment
    2. MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling.

      MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling.

      Proc Natl Acad Sci U S A. 2018 Jan 26;:

      Authors: Dzieran J, Rodriguez Garcia A, Westermark UK, Henley AB, Eyre Sánchez E, Träger C, Johansson HJ, Lehtiö J, Arsenian-Henriksson M

      Read Full Article
      Mentions: MYCN
    3. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma.

      Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma.

      Pediatr Blood Cancer. 2018 Jan 19;:

      Authors: Villablanca JG, Ji L, Shapira-Lewinson A, Marachelian A, Shimada H, Hawkins RA, Pampaloni M, Lai H, Goodarzian F, Sposto R, Park JR, Matthay KK

      Read Full Article
      Mentions: Refractory NANT MYCN
    4. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma

      The New Approaches to Neuroblastoma Therapy Response Criteria (NANTRC) were developed to optimize response assessment in patients with recurrent/refractory neuroblastoma. Response predictors and associations of the NANTRC version 1.0 (NANTRCv1.0) and prognostic factors with outcome were analyzed.

      Read Full Article
      Mentions: Refractory NANT MYCN
    5. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.

      The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.

      Cancer Immunol Immunother. 2018 Jan 11;:

      Authors: Nguyen R, Houston J, Chan WK, Finkelstein D, Dyer MA

      Read Full Article
      Mentions: Antibody
    6. Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome.

      Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome.

      Oncotarget. 2017 Dec 05;8(63):106820-106832

      Authors: Claeys S, Denecker G, Cannoodt R, Kumps C, Durinck K, Speleman F, De Preter K

      Abstract Background: Neuroblastoma is an aggressive childhood malignancy of the sympathetic nervous system. Despite multi-modal therapy, survival of high-risk patients remains disappointingly low, underscoring the need for novel treatment strategies.

      Read Full Article
      Mentions: Treatment ALK MYCN
    7. Late effects of treatment in survivors of childhood cancers: A single-centre experience.

      Late effects of treatment in survivors of childhood cancers: A single-centre experience.

      Indian J Med Res. 2017 Aug;146(2):216-223

      Authors: Seth R, Singh A, Seth S, Sapra S

      Abstract BACKGROUND & OBJECTIVES: With improved survival of childhood cancer patients, the number of long-term cancer survivors is increasing. Some studies have assessed the long-term morbidity after childhood cancer treatment in the developing countries.

      Read Full Article
    8. Review: The role of radiolabeled DOTA-conjugated peptides for imaging and treatment of childhood neuroblastoma.

      Review: The role of radiolabeled DOTA-conjugated peptides for imaging and treatment of childhood neuroblastoma.

      Curr Radiopharm. 2017 Dec 14;:

      Authors: Alexander N, Vali R, Ahmadzadehfar H, Shammas A, Baruchel S

      Abstract Childhood neuroblastoma is a heterogenous disease with varied clinical presentation and biology requiring different approaches to investigation and management.

      Read Full Article
    9. Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma.

      Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma.

      Pediatr Hematol Oncol. 2017 Dec 04;:1-12

      Authors: Whittle SB, Williamson KC, Russell HV

      Abstract High-risk neuroblastoma is an aggressive childhood cancer with poor outcomes. Treatment begins with an induction phase comprised of intense multi-agent chemotherapy with the goal of maximally reducing tumor bulk.

      Read Full Article
    10. New developments in immunotherapy for pediatric solid tumors.

      New developments in immunotherapy for pediatric solid tumors.

      Curr Opin Pediatr. 2017 Nov 20;:

      Authors: Schultz LM, Majzner R, Davis KL, Mackall C

      Abstract PURPOSE OF REVIEW: Building upon preclinical advances, we are uncovering immunotherapy strategies that are translating into improved outcomes in tumor subsets. Advanced pediatric solid tumors carry poor prognoses and resultant robust efforts to apply immunotherapy advances to pediatric solid tumors are in progress.

      Read Full Article
      Mentions: Immunotherapy
    11. YmAbs Announces Closing of $30 Million Extension of Private Equity Placement

      NEW YORK--(BUSINESS WIRE)--Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced that, further to its press release dated October 24, 2017, the Company has completed an extended closing of an additional $30 million in a private equity placement, adding institutional investors Sofinnova Ventures and Scopia Capital Management to its list of shareholders. Together, with the $50 million raised in the fi

      Read Full Article
      Mentions: Immunotherapy
    12. Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

      Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

      Oncoimmunology. 2017;6(11):e1358331

      Authors: Cheung IY, Kushner BH, Modak S, Basu EM, Roberts SS, Cheung NV

      Read Full Article
      Mentions: Antibody
    13. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.

      Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.

      Pediatr Hematol Oncol. 2017 Nov 17;:1-12

      Authors: Berthold F, Hömberg M, Proleskovskaya I, Mazanek P, Belogurova M, Ernst A, Sterba J

      Read Full Article
      Mentions: Treatment MYCN
    14. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

      Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

      MAbs. 2017 Nov 09;:0

      Authors: Mueller I, Ehlert K, Endres S, Pill L, Siebert N, Kietz S, Brock P, Garaventa A, Valteau-Couanet D, Janzek E, Hosten N, Zinke A, Barthlen W, Varol E, Loibner H, Ladenstein R, Lode HN

      Read Full Article
    15. Emerging and investigational therapies for neuroblastoma.

      Emerging and investigational therapies for neuroblastoma.

      Expert Opin Orphan Drugs. 2017;5(4):355-368

      Authors: Applebaum MA, Desai AV, Glade Bender JL, Cohn SL

      Abstract INTRODUCTION: Treatment for children with clinically aggressive, high-risk neuroblastoma remains challenging. Less than 50% of patients with high-risk neuroblastoma will survive long-term with current therapies, and survivors are at risk for serious treatment-related late toxicities.

      Read Full Article
      Mentions: Treatment
    16. LMO1 polymorphisms reduce neuroblastoma risk in Chinese children: a two-center case-control study.

      LMO1 polymorphisms reduce neuroblastoma risk in Chinese children: a two-center case-control study.

      Oncotarget. 2017 Sep 12;8(39):65620-65626

      Authors: Zhang J, Lin H, Wang J, He J, Zhang D, Qin P, Yang L, Yan L

      Abstract Previous genome-wide association and validation studies suggest that LIM domain only 1 (LMO1) gene polymorphisms affect neuroblastoma susceptibility.

      Read Full Article
    17. NIH Funds Pediatric Data Resource Center.

      NIH Funds Pediatric Data Resource Center.

      Cancer Discov. 2017 Oct 11;:

      Authors:

      Abstract Children's Hospital of Philadelphia will lead a collaborative effort-funded with $14.8 million from the NIH-to pool genomic and phenotypic data from tens of thousands of patients to study the causes of pediatric cancer and structural birth defects.

      PMID: 29021134 [PubMed - as supplied by publisher]

      Read Full Article
    18. Retrospective analysis of relapsed abdominal high-risk neuroblastoma.

      Retrospective analysis of relapsed abdominal high-risk neuroblastoma.

      J Pediatr Surg. 2017 Sep 11;:

      Authors: Dübbers M, Simon T, Berthold F, Fischer J, Volland R, Hero B, Cernaianu G

      Abstract BACKGROUND/PURPOSE: The impact of abdominal topography and surgical technique on resectability and local relapse pattern of relapsed abdominal high-risk neuroblastoma (R-HR-NB) is not clearly defined.

      Read Full Article
      Mentions: Treatment Relapse
    19. Hepatic Sinusoidal-obstruction Syndrome and Busulfan-induced Lung Injury in a Post-autologous Stem Cell Transplant Recipient.

      Hepatic Sinusoidal-obstruction Syndrome and Busulfan-induced Lung Injury in a Post-autologous Stem Cell Transplant Recipient.

      Indian Pediatr. 2017 Sep 15;54(9):765-770

      Authors: Jain R, Gupta K, Bhatia A, Bansal A, Bansal D

      Abstract Veno-occlusive disease of the liver is mostly encountered as a complication of hematopoietic stem cell transplantation with myeloablative regimens with an incidence estimated to be 13.7%.

      Read Full Article
    20. Diet, exercise modifications can have ‘tremendous impact’ on pediatric cancer outcomes

      Joya Chandra Keri Schadler Diet and exercise may improve treatment outcomes among pediatric patients with cancer, according to a study conducted at The University of Texas MD Anderson Children’s Cancer Hospital. In addition, introducing energy balance interventions may reduce the risk for late effects during survivorship. Researchers at MD Anderson reviewed 67 pediatric oncology studies to evaluate the relationship between diet and exercise.

      Read Full Article
      Mentions: Treatment
    21. GATA3 is a reliable marker for neuroblastoma in limited samples, including FNA Cell Blocks, core biopsies, and touch imprints.

      GATA3 is a reliable marker for neuroblastoma in limited samples, including FNA Cell Blocks, core biopsies, and touch imprints.

      Cancer. 2017 Oct 04;:

      Authors: Wiles AB, Karrs JX, Pitt S, Almenara J, Powers CN, Smith SC

      Abstract BACKGROUND: Neuroblastomas (NBs) are the most common solid cancer of childhood and infancy; however, in poorly differentiated forms, they present diagnostic challenges.

      Read Full Article
    1-24 of 168 1 2 3 4 5 6 7 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (1 articles) MYCN
  4. General Informations in the News

    1. (1 articles) Treatment